Urine Biomarkers for Prostate Cancer Diagnosis and Progression-Reference-Cited by-同舟云学术

Urine Biomarkers for Prostate Cancer Diagnosis and Progression

Published:2021-05-14 Issue:3 Volume:2 Page:159-170
ISSN:2563-6499
Container-title:Société Internationale d’Urologie Journal
language:
Short-container-title:

Author:

Clark Jeremy,Hurst Rachel,Winterbone Mark Simon,Pahndha Hardeve,Perry Antoinnette,McGrath Sophie,Morgan Richard,Connor Adele E.,Jordan Asia C,Winrow Deirdre,Cooper Colin

Abstract

Prostate cancer (PCa) can be highly heterogeneous and multifocal, and accurate assessment of the volume, grade, and stage of PCa in situ is not a simple task. Urine has been investigated as a source of PCa biomarkers for over 70 years, and there is now strong evidence that analysis of urine could provide more accurate diagnosis and a better risk stratification that could aid clinical decisions regarding disease surveillance and treatment. Urine diagnostics is a developing area, moving towards multiomic biomarker integration for improved diagnostic performance. Urine tests developed by strong collaborations between scientists and clinicians have the potential to provide targeted and meaningful data that can guide treatment and improve men’s lives.

Publisher

Societe Internationale dUrologie

Reference106 articles.

1. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer.2004 Jun 1;100(11):2362–6.

2. 2. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet.2015 Mar 2.

3. 3. Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol.1991 Nov;68(5):499–509.

4. 4. Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int.2009 Jan;103(1):43–8.

5. 5. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol.2012 May;61(5):1019–24.